| Date | Title | Description |
| 24.05.2024 | YS Biopharma Announces Name Change to LakeShore Biopharma | GAITHERSBURG, Md., May 24, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and deliverin... |
| 22.05.2024 | YS Biopharma Announces Results of Extraordinary General Meeting | GAITHERSBURG, Md., May 22, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and deliverin... |
| 08.05.2024 | YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer | GAITHERSBURG, Md., May 8, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering... |
| 29.04.2024 | YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule | GAITHERSBURG, Md., April 29, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and deliver... |
| 19.04.2024 | YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024 | GAITHERSBURG, Md., April 19, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and deliver... |
| 18.04.2024 | YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine | GAITHERSBURG, Md., April 18, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and deliver... |
| 16.04.2024 | YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024 | GAITHERSBURG, Md., April 16, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and deliver... |
| 09.04.2024 | YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine | GAITHERSBURG, Md., April 9, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and deliveri... |
| 03.04.2024 | YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility | GAITHERSBURG, Md., April 3, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and deliveri... |
| 14.11.2023 | Noble Capital Markets Initiates Coverage on YS Biopharma With Outperform Rating and US$5.25 Price Target | GAITHERSBURG, Md., Nov. 14, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and deliveri... |
| 31.10.2023 | YS Biopharma Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine | GAITHERSBURG, Md., Oct. 31, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and deliveri... |
| 26.10.2023 | YS Biopharma Announces Receipt of Nasdaq Notice | GAITHERSBURG, Md., Oct. 26, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and deliveri... |
| 26.09.2023 | YS Biopharma Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine | GAITHERSBURG, Md., Sept. 26, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and deliver... |
| 15.09.2023 | YS Biopharma Granted Patent in the U.S. for Immunotherapy Targeting Chronic Hepatitis B Virus Infection | GAITHERSBURG, Md., Sept. 15, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and deliver... |
| 05.09.2023 | YS Biopharma to Participate in Citi's 18th Annual Biopharma Conference | GAITHERSBURG, Md., Sept. 5, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and deliveri... |
| 25.08.2023 | YS Biopharma Announces Purchase of Shares by Company Officers | GAITHERSBURG, Md., Aug. 25, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and deliveri... |
| 16.08.2023 | YS Biopharma Announces Unaudited Financial Results for the First Quarter of Fiscal Year 2024 | Pipeline makes progress towards commercialization as robust demand for YSJA rabies vaccine continues
Gross margin increases to 80.3%; balance sheet remains strong
GAITHERSBURG, Md., Aug. 16, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASD... |
| 11.08.2023 | YS Biopharma to Report First Quarter Fiscal Year 2024 Financial Results on August 15, 2023 | GAITHERSBURG, Md., Aug. 10, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and deliveri... |
| 27.07.2023 | YS Biopharma Announces Financial Results for Fiscal Year 2023 Ended March 31, 2023 | Total revenues increase by 36.3% year-over-year; gross margin improves to 77.7%; balance sheet remains robust
Company's PIKA rabies vaccine approved for Phase III clinical trials in Singapore, the Philippines, and Pakistan; interim results ... |
| 25.11.2022 | YS Biopharma Received Qualified Person Declaration for Its PIKA COVID-19 Vaccine Facility from European Union GMP | SINGAPORE – Media OutReach – 25 November 2022 – YS Biopharma Co., Ltd. (“YS Biopharma” or the “Company”), a global biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines... |
| 16.11.2022 | YS Biopharma Received Qualified Person Declaration for Its PIKA COVID-19 Vaccine Facility from European Union GMP | GAITHERSBURG, Maryland, Nov. 15, 2022 /PRNewswire/ -- YS Biopharma Co., Ltd. ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing n... |
| 16.11.2022 | YS Biopharma Received Qualified Person Declaration for Its PIKA COVID-19 Vaccine Facility from European Union GMP | GAITHERSBURG, Maryland, Nov. 16, 2022 /PRNewswire/ -- YS Biopharma Co., Ltd. ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing n... |
| 10.11.2022 | YS Biopharma Announces US FDA Clearance Of IND Application For PIKA COVID-19 vaccine | NEW YORK, Nov. 10, 2022 /PRNewswire/ -- YS Biopharma Co., Ltd. ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations... |
| 08.09.2022 | YishengBio Received Approvals From Philippines and UAE For Phase 2 / 3 Clinical Trials of PIKA Recombinant COVID-19 vaccine | BEIJING, Sept. 8, 2022 /PRNewswire/ -- YishengBio Co., Ltd., ("YishengBio"), a biopharmaceutical company dedicated to discovery, development, manufacturing and commercialization of new generations of vaccines and therapeutic biolo... |
| 19.07.2021 | YishengBio Announces PIKA recombinant COVID-19 vaccine received Phase I clinical trial IND clearance from the UAE | BEIJING, July 19, 2021 /PRNewswire/ -- YishengBio Co., Ltd ("YishengBio") today announced that it has received IND clearance for PIKA recombinant COVID-19 vaccine to conduct Phase I clinical trial from United Arab Emirates Ministr... |
